<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T11:55:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/zbk4tn7p9r.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/zbk4tn7p9r.1</identifier>
                <datestamp>2019-11-27T01:57:53Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Wong, Bernice</dc:creator>
    <dc:title>Commercially available Mfsd2a antibody (Abcam, #ab105399) is non-specific</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>A recent article was published last month in Science Advances by Jia Zhou et al entitled “Zika virus degrades the ω-3 fatty acid transporter Mfsd2a in brain microvascular endothelial cells and impairs lipid homeostasis.” The conclusions that Zika virus infection downregulates Mfsd2a protein levels at the blood-brain barrier rely on the quality of the Mfsd2a antibody that they used, which was purchased from Abcam (#ab105399). The Silver lab discovered the function of Mfsd2a as a lysolipid transporter [1] and have published our findings using our own validated antibodies to Mfsd2a [1-9] that we have provided to other researchers who have confirmed their specificity [10-12].  It is disconcerting that there are more than 10 published articles in the literature that have relied on ab105399 for data generation without proof of validation of specificity.  This figure shows a side-by-side test of ab105399 versus our published antibody against Mfsd2a, where we show that ab105399 does not detect Mfsd2a with any specificity. Note: #ab105399 appears to be distributed by Invitrogen (#PA5-21049), Genetex (#GTX85147), ProSci incorporated (#6025), and LSBio (#LS-B5348).

References:
1.	Nguyen, L.N., et al., Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature, 2014. 509(7501): p. 503-6.
2.	Alakbarzade, V., et al., A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome. Nat Genet, 2015. 47(7): p. 814-7.
3.	Berger, J.H., M.J. Charron, and D.L. Silver, Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PLoS One, 2012. 7(11): p. e50629.
4.	Chan, J.P., et al., The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain. PLoS Biol, 2018. 16(8): p. e2006443.
5.	Guemez-Gamboa, A., et al., Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome. Nat Genet, 2015. 47(7): p. 809-13.
6.	Harel, T., et al., Homozygous mutation in MFSD2A, encoding a lysolipid transporter for docosahexanoic acid, is associated with microcephaly and hypomyelination. Neurogenetics, 2018. 19(4): p. 227-235.
7.	Piccirillo, A.R., et al., The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8(+) Memory T Cell Maintenance and Secondary Response to Infection. J Immunol, 2019. 203(1): p. 117-126.
8.	Quek, D.Q., et al., Structural insights into the transport mechanism of the human sodium-dependent lysophosphatidylcholine transporter Mfsd2a. J Biol Chem, 2016.
9.	Wong, B.H., et al., Mfsd2a Is a Transporter for the Essential omega-3 Fatty Acid Docosahexaenoic Acid (DHA) in Eye and Is Important for Photoreceptor Cell Development. J Biol Chem, 2016. 291(20): p. 10501-14.
10.	Wang, Y., et al., Elife, 2019. 8.
11.	Vanlandewijck, M., et al., Nature, 2018.
12.	Byrne, L.C., et al., Mol Ther, 2015. 23(2): p. 290-6.</dc:description>
    <dc:subject>Nutrition</dc:subject>
    <dc:subject>Placenta</dc:subject>
    <dc:subject>Lipid</dc:subject>
    <dc:subject>Brain Cancer</dc:subject>
    <dc:subject>Brain</dc:subject>
    <dc:subject>Transporter Protein</dc:subject>
    <dc:subject>Antibody</dc:subject>
    <dc:subject>Blood-Brain Barrier</dc:subject>
    <dc:subject>Maternal Transfer</dc:subject>
    <dc:subject>Brain Development</dc:subject>
    <dc:subject>Lysophospholipids</dc:subject>
    <dc:subject>Zika Virus</dc:subject>
    <dc:subject>Docosahexaenoic Acid</dc:subject>
    <dc:subject>Microcephaly</dc:subject>
    <dc:contributor>Silver, David</dc:contributor>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/zbk4tn7p9r.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/zbk4tn7p9r.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/zbk4tn7p9r</dc:relation>
    <dc:date>2019-11-27T01:57:53Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
